WENZHOU,China,Feb. 24,2025-- ZK International Group Co.,Ltd. (Nasdaq: ZKIN) ("ZK International" or the "Company"),a leading engineering Company focused on high-performance steel p

Air Premia to Adopt IATA Turbulence Aware Starting March 1,2025 Real-Time Turbulence Data to Enhance Safety and Passenger Comfort

SHENZHEN,China,Feb. 24,2025-- 1MORE introduces the 1MORE SonoFlow Mini Hearing Protection Study Headphones HQ20,and SonoFlow SE Over-Ear Headphones HQ31 two devices supplement the product line with di

Shenzhen, known as the "Capital of Technology" and the "City of the Future", stands as a global innovation powerhouse driving the future of tech. Home to world-renowned tech giants such as Tencent, Huawei, and DJI, Shenzhen has cemented its position as a hub for cutting-edge industries. The city thrives in areas like artificial intelligence, big data, cloud computing, and the low-altitude economy, while also hosting prestigious universities and leading research institutions. As an international coastal metropolis, Shenzhen is celebrated for its openness, inclusivity, green ecological initiativ

STEINHAGEN,Germany,Feb. 20,2025-- Plasmatreat,a leading company in the field of surface treatment with plasma technology,developed the REDOX-Tool: an environmentally friendly,chemical-free solution f

HYDERABAD,India,Feb. 21,2025-- Astreya,a global leader in IT managed services and digital transformation,proudly celebrates the one-year anniversary of its Hyderabad facility. Over the past year,this

BANGKOK,Feb. 20,2025-- King Chulalongkorn Memorial HospitalandThai Red Cross Societyhavelaunched the "Check PD" application for Parkinson\'s risk screeningafter statistics show that the dise

HONG KONG,Feb. 20,2025-- Autohome Inc.(NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"),the leading online destination for automobile consumers in China,today announced its f

CAMBRIDGE,Mass.,ROTTERDAM,Netherlands and SHANGHAI,Feb. 20,2025-- Harbour BioMed (HKEX: 02142,the "Company"),a global biopharmaceutical company committed to the discovery,development and co

YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1